July 2019
Volume 60, Issue 9
ARVO Annual Meeting Abstract  |   July 2019
Retreatment needs of patients with proliferative diabetic retinopathy treated with ranibizumab, laser or combination therapy
Author Affiliations & Notes
  • Andreas Stahl
    University Eye Hospital Greifswald, Greifswald, Germany
  • Sandra Liakopoulos
    Ophthalmology, University of Cologne, Germany
  • Katrin Lorenz
    University Medical Center, Johannes Gutenberg University Mainz, Germany
  • Claudia Quiering
    Novartis Pharma, Germany
  • Laureen Sander
    Novartis Pharma, Germany
  • Georg Spital
    St. Franziskus-Hospital Münster, Germany
  • Gabriele E Lang
    University Eye Hospital Ulm, Germany
  • Footnotes
    Commercial Relationships   Andreas Stahl, Allergan (R), Bayer (C), Bayer (R), Boehringer Ingelheim (C), Novartis (F), Novartis (C), Novartis (R); Sandra Liakopoulos, Allergan (R), Bayer (R), Carl Zeiss Meditec (F), Heidelberg Engineering (R), Novartis (R), Novartis (C); Katrin Lorenz, Aerie Pharmaceuticals (F), Alimera (R), Allergan (R), Bioeq (R), Boehringer Ingelheim (C), Boehringer Ingelheim (R), Chomp Assign (R), Daiichi (R), Isarna Therapeutics (C), Isarna Therapeutics (R), Johnson&Johnson (R), Novartis (C), Novartis (R), Pfizer (R), Quark Pharmaceuticals (R), Regeneron (R), Roche (C), Roche (R), Santen (R), Sensimed (R), Shire (R), Synteract HCR (C), ThromboGenics (R); Claudia Quiering, Novartis (E); Laureen Sander, Novartis (E); Georg Spital, Allergan (R), Bayer (R), Heidelberg Engineering (R), Novartis (R), Pfizer (R); Gabriele Lang, Alcon (F), Alimera (F), Allergan (F), Bayer (F), Boehringer Ingelheim (F), Boehringer Ingelheim (C), Carl Zeiss Meditec (F), Novartis (F), Novartis (C)
  • Footnotes
    Support  Novartis
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1734. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Andreas Stahl, Sandra Liakopoulos, Katrin Lorenz, Claudia Quiering, Laureen Sander, Georg Spital, Gabriele E Lang; Retreatment needs of patients with proliferative diabetic retinopathy treated with ranibizumab, laser or combination therapy. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1734.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To investigate retreatment rates after 1 year of ranibizumab, panretinal laser photocoagulation (PRP) or combination therapy in patients with proliferative diabetic retinopathy (PDR) in the PRIDE study.

Methods : The PRIDE study (NCT01594281) is a Phase II, multicenter, open-label but central reading center-blinded, randomized, controlled study evaluating treatment of patients with PDR with no macular edema. Patients were randomized 1:1:1 to the three treatment arms and treated as needed for 12 months in the core phase of the study (full analysis set: n=106). Thereafter, patients were followed-up observationally in a non-interventional follow-up period with two visits at Month 18 and 24 to assess further outcomes and whether additional treatment was required. 73 patients of the initially enrolled population were included in the analysis of the observational second year follow-up with treatment at the investigators discretion.

Results : In the first year of the study, patients in the ranibizumab and combination group received 3 initial injections followed by 2.3 ± 2.1 or 2.1 ± 2.1 additional injections (mean ± SD), respectively. Patients in the combination group were treated with 1,670 ± 568 laser spots, patients in the PRP group with 1,919 ± 673 laser spots (mean ± SD). In the observational second year, 68% of the patients in the ranibizumab group (n=28) received – at the investigators discretion - PRP treatment (all of them for PDR) and 7% anti-VEGF injections (1 patient for DME, 1 for PDR). In the combination group (n=25), 48% of the patients received PRP (1 for DME, 11 for PDR) and 32% anti-VEGF medication (4 for DME, 3 for PDR, 1 for post-cataract prophylaxis). In the former PRP group (n=20), 40% of the patients received additional PRP (1 for DME, 1 for hemorrhage, 6 for PDR) and 30% anti-VEGF injections (5 for DME, 1 for PDR) in the second year.

Conclusions : Observational follow-up data from the PRIDE study show that PDR often requires continuous treatment beyond the first year either with anti-VEGF, laser therapy or a combination of both. At investigators' discretion, laser treatment was used more frequently in patients who received no PRP treatment in the first year, whereas anti-VEGF was used more frequently in the PRP or combination pre-treatment group than in the ranibizumab monotherapy pre-treatment group.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.